Sekisui Diagnostics, a global diagnostics company, and Qualigen Inc, a leader in the development, manufacturing and marketing of innovative medical diagnostic products, announced a new strategic partnership, encompassing both current business and future collaboration opportunities. Effective immediately Sekisui Diagnostics will assume commercial activities and distribution management for the FastPack IP System and associated products in the US and international markets.

The FastPack IP System is an established, point of care immunoassay Fast packsystem designed to enable physician office laboratories (POLs) to offer key quantitative test results where there is immediate clinical value. The test menu includes vitamin D, testosterone, TSH, free T4, PSA, and hCG.

"Sekisui Diagnostics is delighted to announce our new relationship with Qualigen which will add to our existing rapid test portfolio in POL markets," said Robert Schruender, president and COO of Sekisui Diagnostics. “This system is highly compatible with our business channels and relationship with distributors, especially McKesson. It also offers the potential to strengthen our portfolio in the mid-to-long term.”

“Qualigen is excited to partner with Sekisui Diagnostics in expanding commercial opportunities for the FastPack IP System, which is well proven in the market,” said Paul Rosinack, president and CEO of Qualigen. “Our technology and platform creates synergies with their portfolio, which will add another dimension to our long term growth.”